Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?
Sponsor: Sheppard Pratt Health System
Terminated
Funding no longer available and PI no longer working at the institution
Other Schizoaffective Disorder trials with similar outcome
A PHASE2 clinical study on Schizoaffective Disorder and Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Sheppard Pratt Health System and has accumulated 9 data snapshots since 2014. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sheppard Pratt Health System
For direct contact, visit the study record on ClinicalTrials.gov .